Senate Bill 450

Sponsored by Senator BONHAM (Presession filed.)

SUMMARY

The following summary is not prepared by the sponsors of the measure and is not a part of the body thereof subject to consideration by the Legislative Assembly. It is an editor's brief statement of the essential features of the measure as introduced.

Exempts from labeling requirements drug intended to reverse opioid overdose when drug is dispensed by physician or physician assistant.

A BILL FOR AN ACT

Relating to opioids.

Be It Enacted by the People of the State of Oregon:

SECTION 1. Section 2 of this 2023 Act is added to and made a part of ORS chapter 677.

SECTION 2. The requirements of ORS 677.089 (3) and 677.511 (5) do not apply to a drug approved by the United States Food and Drug Administration for the reversal of an opioid overdose if the drug is:

(1) In the form of a nasal spray; and

(2) Personally dispensed by a physician or physician assistant at the location of practice of the physician or physician assistant.

SECTION 3. Section 2 of this 2023 Act applies to dispensations made on or after the effective date of this 2023 Act.